Nicotinic Alpha1beta1deltagamma Receptor: A Potential Drug Target for Neuropsychiatric Disorders

Target Name: Nicotinic alpha1beta1deltagamma Receptor

NCBI ID: P32833

Nicotinic alpha1beta1deltagamma Receptor

Other Name(s): nAChR alpha1beta1deltagamma

Nicotinic Alpha1beta1deltagamma Receptor: A Potential Drug Target for Neuropsychiatric Disorders

The Nicotinic alpha1beta1deltagamma receptor (nAChR alpha1beta1deltagamma) is a protein that plays a crucial role in the body's nervous system. It is a key regulator of neurotransmitter release and is involved in a wide range of physiological processes, including mood regulation, pain perception, and movement.

The nAChR alpha1beta1deltagamma receptor is a transmembrane protein that is composed of two subunits, alpha and beta. The alpha subunit consists of an extracellular region that includes a long N-terminus, a transmembrane segment, and a C-terminus that is involved in protein-protein interactions. The beta subunit is a short alpha-helical protein that contains a putative G protein-coupled receptor (GPCR) domain.

The nAChR alpha1beta1deltagamma receptor is involved in a wide range of physiological processes, including neurotransmitter release, pain perception, and movement.

One of the key functions of the nAChR alpha1beta1deltagamma receptor is its role in neurotransmitter release. The alpha subunit of the nAChR alpha1beta1deltagamma receptor is involved in the regulation of neurotransmitter release from axons in the central nervous system (CNS). This involves the interaction between the alpha subunit and the neurotransmitter release-related protein, Neuron-Specific protein (NSP).

The nAChR alpha1beta1deltagamma receptor is also involved in pain perception and movement. The alpha subunit of the nAChR alpha1beta1deltagamma receptor is involved in the regulation of pain perception and the modulation of muscle tone. This involves the interaction between the alpha subunit and the pain perception-related protein, TrkA.

Another function of the nAChR alpha1beta1deltagamma receptor is its role in the regulation of mood. The alpha subunit of the nAChR alpha1beta1deltagamma receptor is involved in the regulation of the brain's reward system, which is responsible for regulating motivation and reward.

The nAChR alpha1beta1deltagamma receptor is a potential drug target for the treatment of a wide range of neuropsychiatric and neurological disorders, including depression, anxiety, and chronic pain. Studies have shown that blocking the nAChR alpha1beta1deltagamma receptor can be an effective way to treat these disorders.

One of the main advantages of the nAChR alpha1beta1deltagamma receptor is its small size and its potential for different drug classes. The alpha subunit of the nAChR alpha1beta1deltagamma receptor is relatively small, which makes it easy to target with small molecules. Additionally, the nAChR alpha1beta1deltagamma receptor is involved in a wide range of physiological processes, which makes it a promising target for the treatment of diverse neuropsychiatric and neurological disorders.

In conclusion, the Nicotinic alpha1beta1deltagamma receptor (nAChR alpha1beta1deltagamma) is a protein that plays a crucial role in the body's nervous system. It is involved in a wide range of physiological processes, including neurotransmitter release, pain perception, and movement. The nAChR alpha1beta1deltagamma receptor is a potential drug target for the treatment of a wide range of neuropsychiatric and neurological disorders.

Protein Name: Nicotinic Alpha1beta1deltagamma Receptor

The "Nicotinic alpha1beta1deltagamma Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nicotinic alpha1beta1deltagamma Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets